

Abstract

The present application relates to the use of an antibody-drug conjugate, and a combined drug and the use thereof. Specifically provided are the use of an antibody-drug conjugate, a combined drug and the use thereof. The antibody-drug conjugate shows a significant pharmacodynamic effect of inhibiting tumor cell growth in various NSCLC cell lines with EGFR mutation expression and various human NSCLC PDX tumor models of AZD9291 drug resistance with EGFR mutation expression. In addition, the combined administration of the antibody-drug conjugate and an anti-PD-1 antibody or an anti-PD-L1 antibody shows a significant synergistic pharmacodynamic effect of inhibiting tumor cell growth in the human NSCLC PDX tumor model of AZD9291 drug resistance with EGFR mutation expression.

No Figure